MCID: MGR001
MIFTS: 48

Migraine Without Aura

Categories: Genetic diseases, Neuronal diseases

Aliases & Classifications for Migraine Without Aura

MalaCards integrated aliases for Migraine Without Aura:

Name: Migraine Without Aura 12 43 15 17
Common Migraine 12 71
Migraine Without Aura, Susceptibility to 6

Classifications:



External Ids:

Disease Ontology 12 DOID:12783
ICD9CM 34 346.1
MeSH 43 D020326
NCIt 49 C117004
SNOMED-CT 67 56097005
ICD10 32 G43.0 G43.009
UMLS 71 C0338480

Summaries for Migraine Without Aura

Disease Ontology : 12 A migraine that is characterized by migraine headaches that are not accompanied by an aura.

MalaCards based summary : Migraine Without Aura, also known as common migraine, is related to headache and alexithymia. An important gene associated with Migraine Without Aura is MGR4 (Migraine, Susceptibility To, 4), and among its related pathways/superpathways are Circadian entrainment and Dopamine-DARPP32 Feedback onto cAMP Pathway. The drugs Norepinephrine and Milnacipran have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and pituitary, and related phenotypes are shRNA abundance <= 50% and behavior/neurological

Related Diseases for Migraine Without Aura

Diseases in the Migraine Without Aura family:

Migraine with or Without Aura 1 Migraine with or Without Aura 2
Migraine with or Without Aura 3 Migraine Without Aura 4
Migraine with or Without Aura 5 Migraine with or Without Aura 6
Migraine with or Without Aura 8 Migraine with or Without Aura 10
Migraine with or Without Aura 11 Migraine with or Without Aura 12
Migraine with or Without Aura 13

Diseases related to Migraine Without Aura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 163)
# Related Disease Score Top Affiliating Genes
1 headache 31.7 SCN1A KCNK18 EDNRA
2 alexithymia 30.5 SLC6A4 HTR1A DRD2
3 migraine with aura 30.4 TRPM8 SLC6A4 SCN1A MTHFR KCNK18 FHL5
4 fibromyalgia 30.3 TNF SLC6A4 DRD2
5 generalized anxiety disorder 30.2 SLC6A4 HTR1A DRD2
6 sleep disorder 30.0 TNF SLC6A4 PRL HTR1A DRD2
7 restless legs syndrome 29.9 SLC6A4 PRL DRD4 DRD3 DRD2
8 panic disorder 29.5 SLC6A4 PRL HTR1A DRD4 DRD3 DRD2
9 migraine with or without aura 1 28.8 TRPM8 TNF SLC6A4 SCN1A PRL PRDM16
10 bipolar disorder 27.9 TNF SLC6A4 PRL MTHFR HTR1A GRIA1
11 migraine without aura 4 12.7
12 migraine, familial hemiplegic, 3 11.4
13 migraine with or without aura 13 11.4
14 carotidynia 11.1
15 polysubstance abuse 10.5 DRD3 DRD2
16 tardive dyskinesia 10.4 DRD3 DRD2
17 idiopathic corneal edema 10.4 DRD4 DRD3 DRD2
18 periodic limb movement disorder 10.4 DRD4 DRD3 DRD2
19 oculogyric crisis 10.4 DRD4 DRD3 DRD2
20 lingual-facial-buccal dyskinesia 10.4 DRD4 DRD3 DRD2
21 chronic tic disorder 10.4 DRD4 DRD3 DRD2
22 galactorrhea 10.4 PRL DRD2
23 choreatic disease 10.4 DRD4 DRD3 DRD2
24 cluster headache 10.3
25 gastroparesis 10.3 DRD4 DRD3 DRD2
26 prolactin producing pituitary tumor 10.3 PRL DRD2
27 familial hemiplegic migraine 10.3
28 oppositional defiant disorder 10.3 SLC6A4 DRD4 DRD2
29 cannabis abuse 10.3 HTR1A DRD4 DRD2
30 neuroleptic malignant syndrome 10.2 HTR1A DRD3 DRD2
31 somatoform disorder 10.2 TRPM8 SLC6A4 SCN1A
32 conduct disorder 10.2 SLC6A4 DRD4 DRD2
33 movement disease 10.2 DRD4 DRD3 DRD2
34 drug dependence 10.2 SLC6A4 DRD3 DRD2
35 tic disorder 10.2 SLC6A4 DRD4 DRD3 DRD2
36 pedophilia 10.2 PRL DRD2
37 radiation proctitis 10.2 TNF EDNRA
38 inhibited male orgasm 10.2 SLC6A4 HTR1A
39 kleptomania 10.2 SLC6A4 HTR1A DRD2
40 hyperprolactinemia 10.2 PRL DRD4 DRD2
41 motion sickness 10.2
42 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
43 stroke, ischemic 10.2
44 allergic hypersensitivity disease 10.2
45 endometriosis 10.2
46 cerebrovascular disease 10.2
47 hemiplegic migraine 10.2
48 chronic pain 10.2
49 amphetamine abuse 10.2 SLC6A4 DRD4
50 avoidant personality disorder 10.2 SLC6A4 DRD4 DRD3 DRD2

Comorbidity relations with Migraine Without Aura via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Migraine Without Aura:



Diseases related to Migraine Without Aura

Symptoms & Phenotypes for Migraine Without Aura

GenomeRNAi Phenotypes related to Migraine Without Aura according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.32 DRD2 DRD3 DRD4 EDNRA HTR1A MEF2D

MGI Mouse Phenotypes related to Migraine Without Aura:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.22 DRD2 DRD3 DRD4 EDNRA GRIA1 HTR1A
2 cardiovascular system MP:0005385 10.07 DRD2 DRD3 EDNRA HTR1A MEF2D PRDM16
3 homeostasis/metabolism MP:0005376 10.07 DRD2 DRD3 DRD4 EDNRA GRIA1 HTR1A
4 integument MP:0010771 9.9 ASTN2 DRD2 EDNRA GRIA1 MTHFR PRDM16
5 digestive/alimentary MP:0005381 9.87 DRD2 DRD3 EDNRA PRDM16 SLC6A4 TGFBR2
6 nervous system MP:0003631 9.86 DRD2 DRD3 DRD4 EDNRA GRIA1 HTR1A
7 skeleton MP:0005390 9.28 DRD2 EDNRA GRIA1 MEF2D MTHFR PHACTR1

Drugs & Therapeutics for Migraine Without Aura

Drugs for Migraine Without Aura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 166)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norepinephrine Approved Phase 4 51-41-2 439260
2
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
3
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
4
Topiramate Approved Phase 4 97240-79-4 5284627
5
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
6
Histamine Approved, Investigational Phase 4 51-45-6 774
7
Promethazine Approved, Investigational Phase 4 60-87-7 4927
8
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
9
Almotriptan Approved, Investigational Phase 4 154323-57-6, 181183-52-8 123606
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
11
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
12
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
13
Acetaminophen Approved Phase 4 103-90-2 1983
14
Haloperidol Approved Phase 4 52-86-8 3559
15 Antidepressive Agents Phase 4
16 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
17 Neurotransmitter Agents Phase 4
18 Anticonvulsants Phase 4
19 Hypoglycemic Agents Phase 4
20 Anesthetics, Local Phase 4
21 Antiemetics Phase 4
22 Gastrointestinal Agents Phase 4
23 Anesthetics Phase 4
24 Dermatologic Agents Phase 4
25 Histamine H1 Antagonists Phase 4
26 Hypnotics and Sedatives Phase 4
27 Antipruritics Phase 4
28 Histamine Antagonists Phase 4
29 Serotonin Agents Phase 4
30
Histamine Phosphate Phase 4 51-74-1 65513
31 Autonomic Agents Phase 4
32 Central Nervous System Depressants Phase 4
33 Serotonin Receptor Agonists Phase 4
34 Anti-Allergic Agents Phase 4
35 Anti-Inflammatory Agents, Non-Steroidal Phase 4
36 Analgesics, Non-Narcotic Phase 4
37 Cyclooxygenase Inhibitors Phase 4
38 Antirheumatic Agents Phase 4
39 Analgesics Phase 4
40 Psychotropic Drugs Phase 4
41 Pharmaceutical Solutions Phase 4
42 Dopamine Agents Phase 4
43 Antipsychotic Agents Phase 4
44 Tranquilizing Agents Phase 4
45 Dopamine Antagonists Phase 4
46 Analgesics, Opioid Phase 4
47 Narcotics Phase 4
48 Dopamine D2 Receptor Antagonists Phase 4
49 Anesthetics, General Phase 4
50 Adjuvants, Anesthesia Phase 4

Interventional clinical trials:

(show top 50) (show all 78)
# Name Status NCT ID Phase Drugs
1 Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine. Unknown status NCT01319825 Phase 4 milnacipran
2 Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled Trial Completed NCT02314351 Phase 4 Metoclopramide 10 mg;Placebo;Fentanyl
3 Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate) Completed NCT00210496 Phase 4 topiramate; almotriptan malate
4 TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study Completed NCT00212810 Phase 4 Topiramate
5 Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department Completed NCT01596166 Phase 4 Ketorolac Tromethamine;Metoclopramide
6 The Comparison of the Effectiveness of Intravenous Dexketoprofen and Paracetamol in the Treatment of Headache Caused by Acute Migraine Attack in Emergency Service Completed NCT01730326 Phase 4 Paracetamol;Dexketoprofen
7 Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the Emergency Department: A Randomized Controlled Trial Completed NCT02098499 Phase 4 Haloperidol;Metoclopramide 10mg;Diphenhydramine
8 A Continuous Study on Abiding Effect of Acupuncture for Migraine Treatment Unknown status NCT01687660 Phase 2, Phase 3
9 Randomised Sham-controlled Trial of Anodal Transcranial Direct Current Stimulation (tDCS) for the Prevention of Episodic Migraine Unknown status NCT02122757 Phase 3
10 A 12-week Prospective, Double-blinded, Randomized, Multicenter Study of Low Dose and Medium Dose Botulinum Toxin Type A (Dysport® ) Injection for Migraine Prophylaxis. Completed NCT00258609 Phase 3 Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection
11 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine Completed NCT00236509 Phase 3 topiramate
12 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine Completed NCT00231595 Phase 3 topiramate
13 Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment: a Randomized, Double Blind Clinical Trial Completed NCT01814189 Phase 3 Sumatriptan+Promethazine (SPr)
14 A Randomized, Double-Blind, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prophylaxis of Migraine Completed NCT00236561 Phase 3 topiramate, propranolol
15 A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Tolerability of TREXIMA* (Sumatriptan Succinate/Naproxen Sodium) for a Single Moderate or Severe Headache in Adults Diagnosed With Probable Migraine Without Aura (ICHD-II 1.6.1) (*TREXIMET) Completed NCT00387881 Phase 3 sumatriptan succinate / naproxen sodium;Placebo
16 Candesartan vs Propranolol for Migraine Prevention: A Double Blind, Placebo Controlled, Double Dummy, Triple Cross-over Study Completed NCT00884663 Phase 2, Phase 3 Candesartan;propranolol;placebo
17 A Multi-Center, Randomized, Parallel, Double-Blind, Placebo-Controlled Study in Evaluation the Efficacy and Safety of Laxymig® ER as Prophylactic Treatment in Patients With Migraine Completed NCT00334178 Phase 3 Laxymig ER (drug)
18 A Multicentre, Dose Optimisation Study to Assess the Consistency of Efficacy of Eletriptan for the Treatment of Migraine (With and Without Aura) Completed NCT01859481 Phase 3 Placebo;Eletriptan HBr 40 mg;Eletriptan HBr 80 mg
19 Single Center, Phase 2B, Randomized, Double-Blind, Placebo, Individual Components, and 2-Doses, Controlled Pilot Study to Assess the Efficacy and Safety of a Single Dose of ALLOD-2 in the Acute Treatment of Migraine (ANODYNE-1) Completed NCT03061734 Phase 2, Phase 3 ALLOD-2;ALLOD-2H;Component A (regular dose);Component B;Placebo
20 Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Completed NCT00471952 Phase 3 Maxalt 10mg MLT plus Caffeine 75mg;Maxalt 10mg MLT plus Placebo;Placebo + Placebo
21 Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches Completed NCT00122278 Phase 3 Dexamethasone
22 EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine Recruiting NCT03901482 Phase 3 Dihydroergotamine;Placebos
23 Safety and Efficacy of De-Novo Algorithm and Formula in the Treatment of Patients With Intractable Chronic Craniofacial Neuralgia, or Chronic Migraine Headaches. Unknown status NCT03220113 Phase 1, Phase 2
24 Intranasal AST-726 Treatment for Prophylaxis of Migraine: A Placebo-Controlled Clinical Study Unknown status NCT00285402 Phase 2 AST-726 Low dose;AST-726 High dose;AST-726 Placebo
25 Multi-centre, Parallel Group, Double-blind, Placebo Controlled Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Completed NCT00311662 Phase 2 Tonabersat;Placebo
26 A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Efficacy, Safety and Tolerability Study of Dronabinol MDI in the Acute Treatment of Migraine Headache Completed NCT00123201 Phase 2 Dronabinol MDI
27 Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN-188 for the Treatment of Moderate to Severe Migraine Headache Without Aura Completed NCT00959751 Phase 2 NXN-188;Placebo
28 Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Migraine. Safety Issues. Completed NCT02259075 Phase 1, Phase 2 Botulinum Toxin Type A
29 Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open Label Extension Completed NCT00534560 Phase 2 Tonabersat;Tonabersat;Placebo
30 Effects of DFN-15 on Migraine With Allodynia Completed NCT03472378 Phase 2 DFN-15
31 A Randomized, Double-blind Placebo-controlled, Parallel Group Study to Study the Efficacy and Tolerability of Ramelteon (Rozerem) in the Prophylaxis of Migraine Terminated NCT00739024 Phase 2 Ramelteon;Placebo
32 Dexamethasone for the Treatment of Established Postoperative Nausea and Vomiting - a Randomised, Placebo-controlled, Dose-finding Study Terminated NCT01975727 Phase 2 Placebo;Dexamethasone 3 mg;Dexamethasone 6 mg;Dexamethasone 12 mg
33 A Randomized, Open-Label, Crossover Study to Evaluate the PK, Bioavailability, Dose Proportionality, Safety, and Tolerability of Single Doses of STS101, DHE Mesylate IM Injection and DHE Mesylate Nasal Spray in Healthy Adult Subjects Completed NCT03874832 Phase 1 Dihydroergotamine
34 A Phase 1, Two-part, Single Dose, Randomised, Double-blind, Placebo-controlled Parallel Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Subcutaneous TRV250 Following Glyceryl Trinitrate Infusion Recruiting NCT04201080 Phase 1 Part A: TRV250-20mg/ml;Placebo;Part B: TRV250 Dose 1;Part B: TRV250 Dose 2;Part B: TRV250 Dose 3;Placebo
35 Cortical Reorganisation in Patients With Primary Headache Disorders Unknown status NCT00263991
36 Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI Unknown status NCT02202486
37 Identification of Inflammatory Markers in Migraine Patients Unknown status NCT00969995
38 Inflammatory Markers Identification in Migraine Patients Unknown status NCT01618201
39 MIBRAIN - Migraine and the Brain: Consequences, Causes, and Vascular Interaction Unknown status NCT01803984
40 Pituitary Adenylate Cyclase-activating Polypeptide (PACAP27) Headache Properties in Migraine Without Aura Patients Completed NCT03471039 PACAP27;Saline
41 Basic Scientific Research Investigating PACAP38 Headache Inducing Effects in Migraine Patients Completed NCT00380263 PACAP38
42 Functional MRI (fMRI) in Patients With Migraine Without Aura Provoked by Completed NCT00363532 infusion of calcitonin gene related peptide (CGRP)
43 The Effect of PACAP38 and VIP on Migraine Patients Assessed by a 3-Tesla MR Scanner Completed NCT01471990 Pituitary Adenylate Cyclase-Activating Polypeptide-38;Vasoactive Intestinal Peptide
44 The Effect of Sumatriptan and Placebo on CGRP Induced Headache Completed NCT03542357 Calcitonin Gene Related Peptide;Sumatriptan 50 mg;Placebo Oral Tablet
45 The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache Completed NCT03422796 Cilostazol 200mg;SUMAtriptan 6 MG/ML;Placebo
46 The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache. Development of a Pragmatic Migraine Model Completed NCT02486276 Cilostazol;Sumatriptan;Placebo
47 Transcriptomic and Biochemical Changes During Spontaneous Attacks of Migraine With Aura and Migraine Without Aura Completed NCT02468622
48 PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load Completed NCT02158221 PACAP
49 Evaluating the Prophylactic Efficacy of Acupuncture for Migraine Without Aura (MWoA) : A Randomized Controlled Trial Completed NCT02765581
50 Greater Occipital and Supraorbital Nerve Blockade For The Preventive Treatment of Migraine Completed NCT03435185

Search NIH Clinical Center for Migraine Without Aura

Cochrane evidence based reviews: migraine without aura

Genetic Tests for Migraine Without Aura

Anatomical Context for Migraine Without Aura

MalaCards organs/tissues related to Migraine Without Aura:

40
Brain, Testes, Pituitary, Cortex, Heart, Endothelial, Skin

Publications for Migraine Without Aura

Articles related to Migraine Without Aura:

(show top 50) (show all 2101)
# Title Authors PMID Year
1
Association between the tumor necrosis factor-alpha -308 G/A gene polymorphism and migraine. 61 6
14718719 2004
2
Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. 6
16418737 2006
3
An association between asthma and TNF-308G/A polymorphism: meta-analysis. 6
16865291 2006
4
Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. 6
14681301 2004
5
Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. 6
12746914 2003
6
Association between G-308A polymorphism of the tumor necrosis factor-alpha gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents. 6
12485196 2002
7
Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease. 6
11826025 2002
8
Relation between tumour necrosis factor polymorphism TNFalpha-308 and risk of asthma. 6
11896460 2002
9
Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. 6
11506397 2001
10
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. 6
11261930 2001
11
Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. 6
10450718 1999
12
Genetic contribution of the tumor necrosis factor region in Guillain-Barré syndrome. 6
9818939 1998
13
Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor alpha with human IDDM. 6
8056188 1994
14
Effect of genetic liability to migraine on coronary artery disease and atrial fibrillation: a Mendelian randomization study. 61
31661179 2020
15
Clinical features of right-to-left shunt in the different subgroups of migraine. 61
32011802 2020
16
The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort. 61
31755111 2020
17
Dysphasia and Other Higher Cortical Dysfunctions During the Migraine Aura-a Systematic Review of Literature. 61
31981018 2020
18
Changes in face and face pareidolia processing in patients with migraine: An ERP study. 61
31940235 2020
19
Headache frequency associates with brain microstructure changes in patients with migraine without aura. 61
31898090 2020
20
Allodynia in Menstrually Related Migraine: Score Assessment by Allodynia Symptom Checklist (ASC-12). 61
31637701 2020
21
Migraine and arterial stiffness in the Brazilian Longitudinal Study of Adult Health: ELSA-Brasil. 61
31907516 2020
22
Sensory Hypersensitivity Symptoms in Migraine With vs Without Aura: Results From the American Registry for Migraine Research. 61
31965576 2020
23
PACAP27 induces migraine-like attacks in migraine patients. 61
31299857 2020
24
Metacognitive impairment in patients with episodic and chronic migraine. 61
31911106 2020
25
An fMRI-based neural marker for migraine without aura. 61
31964691 2020
26
A subjective cognitive impairments scale for migraine attacks: validation of the Italian version of the MIG-SCOG. 61
31897947 2020
27
Association of rs2651899 Polymorphism in the Positive Regulatory Domain 16 and Common Migraine Subtypes: A Meta-Analysis. 61
31557325 2020
28
The epidemiology of headaches among patients with epilepsy: a systematic review and meta-analysis. 61
31924166 2020
29
Migraine-linked characteristics of transcranial magnetic stimulation-induced phosphenes. 61
31912706 2019
30
Temporal instability of salience network activity in migraine with aura. 61
31815918 2019
31
Alterations of individual thalamic nuclei volumes in patients with migraine. 61
31818256 2019
32
Migraine without Aura and Subclinical Atherosclerosis in Young Females: Is Gut Microbiota to Blame? 61
31888137 2019
33
Orofacial Pain and Menstrually Related Migraine. 61
32026457 2019
34
Impaired intrinsic functional connectivity between the thalamus and visual cortex in migraine without aura. 61
31856703 2019
35
[Typical visual aura without headache: a case report.] 61
31833750 2019
36
Headache in Petrous Apicitis: A Case Report of Chronic Migraine-like Headache Due to Peripheral Pathology. 61
31535370 2019
37
Altered functional connectivity of the red nucleus and substantia nigra in migraine without aura. 61
31711434 2019
38
Vision and Hyper-Responsiveness in Migraine. 61
31735863 2019
39
Grey matter changes in patients with vestibular migraine. 61
31451181 2019
40
Subgrouping Factors Influencing Migraine Intensity in Women: A Semi-automatic Methodology Based on Machine Learning and Information Geometry. 61
31677218 2019
41
Could rs4379368 be a genetic marker for North Indian migraine patients with aura?: Preliminary evidence by a replication study. 61
31505242 2019
42
Abnormal cardiovascular response to nitroglycerin in migraine. 61
31594384 2019
43
Major depression subtypes are differentially associated with migraine subtype, prevalence and severity. 61
31645113 2019
44
Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report. 61
31327684 2019
45
A pilot exploratory study comparing the King-Devick test (KDT) during and between migraine attacks. 61
31660762 2019
46
Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. 61
31104505 2019
47
Comparing migraine with and without aura to healthy controls using RNA sequencing. 61
31104508 2019
48
Increased activation of the pregenual anterior cingulate cortex to citalopram challenge in migraine: an fMRI study. 61
31615444 2019
49
Anxiety sensitivity and intentional avoidance of physical activity in women with probable migraine. 61
31260336 2019
50
A web-based, branching logic questionnaire for the automated classification of migraine. 61
31042063 2019

Variations for Migraine Without Aura

ClinVar genetic disease variations for Migraine Without Aura:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TNF TNF, -308G-ASNV risk factor 12388

Expression for Migraine Without Aura

Search GEO for disease gene expression data for Migraine Without Aura.

Pathways for Migraine Without Aura

GO Terms for Migraine Without Aura

Cellular components related to Migraine Without Aura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.97 TRPM8 TNF TGFBR2 SLC6A4 SCN1A KCNK18
2 integral component of plasma membrane GO:0005887 9.28 TNF TGFBR2 SLC6A4 KCNK18 HTR1A EDNRA
3 dopaminergic synapse GO:0098691 9.26 DRD3 DRD2
4 membrane raft GO:0045121 9.26 TRPM8 TNF TGFBR2 SLC6A4

Biological processes related to Migraine Without Aura according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.97 TGFBR2 SLC6A4 MTHFR DRD3 DRD2
2 cellular calcium ion homeostasis GO:0006874 9.83 TRPM8 DRD4 DRD3
3 response to toxic substance GO:0009636 9.82 SLC6A4 DRD3 DRD2
4 response to organic substance GO:0010033 9.8 TNF TGFBR2 SLC6A4
5 social behavior GO:0035176 9.77 SLC6A4 DRD4 DRD3
6 response to amphetamine GO:0001975 9.73 DRD4 DRD3 DRD2
7 arachidonic acid secretion GO:0050482 9.69 DRD4 DRD3 DRD2
8 negative regulation of protein secretion GO:0050709 9.67 DRD4 DRD3 DRD2
9 prepulse inhibition GO:0060134 9.65 DRD3 DRD2
10 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.65 DRD3 DRD2
11 dopamine receptor signaling pathway GO:0007212 9.65 DRD4 DRD3 DRD2
12 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.64 DRD3 DRD2
13 positive regulation of renal sodium excretion GO:0035815 9.63 DRD3 DRD2
14 G protein-coupled receptor internalization GO:0002031 9.63 DRD3 DRD2
15 behavioral response to cocaine GO:0048148 9.63 DRD4 DRD3 DRD2
16 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.62 DRD4 DRD3
17 regulation of potassium ion transport GO:0043266 9.61 DRD3 DRD2
18 regulation of dopamine metabolic process GO:0042053 9.61 HTR1A DRD4
19 synaptic transmission, dopaminergic GO:0001963 9.61 DRD4 DRD3 DRD2
20 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.59 DRD3 DRD2
21 negative regulation of dopamine receptor signaling pathway GO:0060160 9.58 DRD3 DRD2
22 regulation of neurotransmitter uptake GO:0051580 9.58 DRD3 DRD2
23 vasoconstriction GO:0042310 9.58 SLC6A4 HTR1A EDNRA
24 regulation of locomotion involved in locomotory behavior GO:0090325 9.55 DRD3 DRD2
25 response to hypoxia GO:0001666 9.55 TGFBR2 SLC6A4 MTHFR EDNRA DRD2
26 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.54 DRD4 DRD2
27 negative regulation of voltage-gated calcium channel activity GO:1901386 9.54 DRD4 DRD3 DRD2
28 acid secretion GO:0046717 9.52 DRD3 DRD2
29 behavioral response to ethanol GO:0048149 9.5 DRD4 DRD3 DRD2
30 dopamine metabolic process GO:0042417 9.43 DRD4 DRD3 DRD2
31 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.13 DRD4 DRD3 DRD2
32 response to histamine GO:0034776 8.8 DRD4 DRD3 DRD2

Molecular functions related to Migraine Without Aura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.43 DRD4 DRD3 DRD2
2 dopamine binding GO:0035240 9.33 DRD4 DRD3 DRD2
3 serotonin binding GO:0051378 9.32 SLC6A4 HTR1A
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.13 DRD4 DRD3 DRD2
5 dopamine neurotransmitter receptor activity GO:0004952 8.8 DRD4 DRD3 DRD2

Sources for Migraine Without Aura

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....